ASH 2022 | Safety and efficacy of SX-682 in HMA failure MDS
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the results of a Phase I dose-escalation trial of SX-682 in patients with hypomethylating agent (HMA) failure myelodysplastic syndromes (MDS; NCT04245397). SX-682 is a first-in-class inhibitor of the CXCR1/2 chemokine receptors, which aims to eliminate leukemic stem cells while also eradicating myeloid-derived immune suppressor cells. Overall, results suggest SX-682 is well-tolerated and induces a response in patients with HMA failure MDS at even the lowest dose. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Consultancy; Shattuck Labs: Membership on an entity’s Board of Directors or advisory committees; Kite: Membership on an entity’s Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Incyte: Speakers Bureau; Syndax: Membership on an entity’s Board of Directors or advisory committees; Magenta: Consultancy; Intellia: Membership on an entity’s Board of Directors or advisory committees; BMS: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Aprea: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Agios: Membership on an entity’s Board of Directors or advisory committees; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Syntrix Pharmaceuticals: Research Funding; Lixte: Patents & Royalties: LB-100; Nemucore: Membership on an entity’s Board of Directors or advisory committees.
